Protective efficacy of prolonged co-trimoxazole prophylaxis in HIV-exposed children up to age 4 years for the prevention of malaria in Uganda: a randomised controlled open-label trial

Dr Jaco Homsy, Grant Dorsey, Emmanuel Arinaitwe, Humphrey Wanzira, Abel Kakuru, Victor Bigira, Mary Muhindo, Prof Moses R Kamya, Taylor G Sandison, Jordan W Tappero

WHO recommends daily co-trimoxazole for children born to HIV-infected mothers from 6 weeks of age until breastfeeding cessation and exclusion of HIV infection. We have previously reported on the effectiveness of continuation of co-trimoxazole prophylaxis up to age 2 years in these children. We assessed the protective efficacy and safety of prolonging co-trimoxazole prophylaxis until age 4 years in HIV-exposed children.

December 5, 2014
Year of publication
2014
Tags
co-trimoxazole, Prophylaxis, HIV-exposed children, HIV prevention, malaria, HIV infection, HIV, safety and efficacy